1. Introduction {#sec1}
===============

Metaplastic breast cancer (MBC) is a rare histological variant of breast cancer, which is thought to be more aggressive than typical invasive ductal carcinoma \[[@bib1], [@bib2], [@bib3], [@bib4]\]. MBC is associated with high tumor grade, large tumor size, less advanced nodal involvement, and high rates of metastasis \[[@bib5], [@bib6], [@bib7], [@bib8]\]. Triple-negative breast cancers (TNBC) with invasive ductal carcinoma histology are also an aggressive form of breast cancer with absent estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression. This subtype, which comprises 12--17% of breast cancer cases, cannot be effectively treated with targeted therapies to the HER2 receptor or anti-estrogen treatment, and is associated with poorer outcomes than hormone receptor positive disease \[[@bib9]\].

MBC patients usually have a triple-negative phenotype, but exhibit a different gene expression profile compared to those with invasive ductal breast carcinoma. These include higher expression of genes associated with an epithelial to mesenchymal transition (EMT) attributed to acquisition of migratory morphology and dissemination of malignancy, as well as downregulation of genes associated with a chemoresistant phenotype \[[@bib1],[@bib10],[@bib11]\]. While there is limited data to guide management of metaplastic breast cancer due to its infrequency (0.25%--1%) \[[@bib12],[@bib13]\], the available studies support aggressive treatment, including the use of adjuvant radiation therapy (RT) \[[@bib3],[@bib7]\]. Few studies addressing the outcomes comparing TNBC with MBC have been undertaken. While these studies have suggested worse outcomes with MBC, they have been limited by small sample size and short follow up \[[@bib4],[@bib5],[@bib14],[@bib15]\]. The purpose of our study is to further expand on prior studies by evaluating national practice patterns for patients with TNBC and MBC, compared clinical characteristics between these two cohorts of patients, and to determine long-term comparative outcomes using a large, contemporary US cancer database.

2. Materials and methods {#sec2}
========================

This investigation analyzed patients from the National Cancer Database (NCDB), which is a joint project of the Commission on Cancer (CoC) of the American College of Surgeons and the American Cancer Society. The database consists of de-identified information regarding tumor characteristics, patient demographics, and patient survival for approximately 70% of the US population \[[@bib16], [@bib17], [@bib18], [@bib19], [@bib20]\]. The NCDB contains information not included in the Surveillance, Epidemiology, and End Results database, including details regarding use of systemic therapy and radiation dose. The data used in this study were derived from a de-identified NCDB file. The American College of Surgeons and the CoC have not verified and are neither responsible for the analytic or statistical methodology employed nor the conclusions drawn from these data by the investigators. As all patient information in the NCDB database is de-identified, this study was exempt from institutional review board evaluation.

Inclusion criteria for this study were women with newly-diagnosed, T1-4N0-3M0 breast cancer with either MBC histology (International Classification of Disease \[ICD\]-0-3 codes 8560, 8562, 8570--8572, 8575, and 8980--8982) or TNBC with infiltrating ductal carcinoma histology (ICD-0-3 8500). In order for including, a complete record of clinical staging for T, N, and M stage was required. Cases with unknown information regarding chemotherapy, radiation, definitive surgical therapy, and vital status were excluded. The χ^2^ test analyzed categorical frequencies between groups non-parametrically. Multivariate logistic regression was used to determine characteristics associated to a greater extent with MBC as compared to TNBC. The Kaplan-Meier method was used for survival analysis, with comparisons between the groups made using the log-rank test. Overall survival (OS) was defined as the interval between the date of diagnosis and the date of death, or censored at last contact. Subset analysis was performed to compare OS between patients with either TNBC or MBC while stratifying patients by T stage and N stage. Subset analysis was also performed for estrogen receptor positive (ER+) MBC patients while stratifying patients based on receipt of hormonal therapy. Cox multivariable analysis was performed to determine factors associated with overall survival using variables that showed statistical significance on univariate analysis.

Due to imbalances between the arms, propensity score matching (PSM) was performed to compare survival outcomes between different groups. Statistically significant variables from multivariate Cox analysis were included for matching. These variables included age, race, Charlson Deyo score, insurance status, median income, year of diagnosis, T stage, N stage, grade, chemotherapy receipt, RT receipt, and HER2 status. Specifically, PSM balanced these variables through matching and provided a propensity score based on the probability of receiving treatment for the given variables \[[@bib21], [@bib22], [@bib23], [@bib24], [@bib25], [@bib26], [@bib27], [@bib28], [@bib29], [@bib30]\]. Patients from the different groups were paired together based on the similarity of the propensity score. Patients were matched 1:1 without replacement and a caliper of 0.05 was used to ensure balance. Standardized mean differences were determined to check for large imbalances for each variable between the matched cohorts with a value of \<0.1 reflecting a significant imbalance \[[@bib31]\]. Data was analyzed using SPSS (IBM Corp. Version 24.0. Armonk, NY).

3. Results {#sec3}
==========

A complete flow diagram with inclusion criteria is provided in [Fig. 1](#fig1){ref-type="fig"}. In all, 55,847 patients met the inclusion criteria. Of these, 50,705 (90.8%) patients had TNBC and 5,142 (9.2%) had MBC. [Table 1](#tbl1){ref-type="table"} shows the clinical and demographic characteristics for the patients included in the study. A greater proportion of patients with MBC compared to those with TNBC were over 65 years of age; had T2-4, N0 and well differentiated disease; and received treatment with mastectomy. MBC patients were less likely to have private insurance or receive treatment with either chemotherapy or RT. Of note, most patients were Caucasian, had pN0 disease discovered on pathology, poorly differentiated or anaplastic grade, and fewer comorbidities. 25.4% of MBC and 26.5% of TNBC patients received an axillary lymph node dissection (number of lymph nodes examined ≥ 10). HER2 status was not recorded in 51.9% of MBC patients compared to 2.3% of TNBC patients.Fig. 1Patient selection diagram.Fig. 1Table 1Baseline characteristics of patients in each of the cohorts.Table 1CharacteristicIntraductal Breast Cancer (N = 50,705)Metastatic Breast Cancer (N = 5142)P valueAge ≤5014,184 (28%)1153 (22.4%)\<0.001 51-6419,729 (38.9%)1760 (34.2%) ≥6516,792 (33.1%)2229 (43.3%)Race White39,586 (78.1%)4198 (81.6%)\<0.001 Black8677 (17.1%)709 (13.8%) Other2442 (4.8%)235 (4.6%)Charlson Deyo Score041,785 (82.4%)4186 (81.4%)0.10217191 (14.2%)756 (14.7%)≥21729 (3.4%)200 (3.9%)Insurance Status Medicaid4450 (8.8%)359 (7.0%)\<0.001 Private27,421 (54.1%)2427 (47.2%) Medicare16,302 (32.2%)2078 (40.4%) Not Insured1362 (2.7%)115 (2.2%) Other1170 (2.3%)163 (3.2%)Median Income ≤ \$6299934,192 (67.4%)3421 (66.5%)\<0.001 ≥ \$6300016,303 (32.2%)1659 (32.3%) Not recorded210 (0.4%)62 (1.2%)Facility Type Academic20,410 (40.3%)2134 (41.5%)0.009 Nonacademic27,371 (53.6%)2742 (53.3%) Not recorded3122 (6.2%)266 (5.2%)Year of Diagnosis 2004--20081308 (2.6%)2077 (40.4%)\<0.001 2009--201349,397 (97.4%)3065 (59.6%)T stage T128,839 (56.9%)1639 (31.9%)\<0.001 T218,355 (3.62%)2490 (48.4%) T32530 (5.0%)736 (14.3%) T4981 (1.9%)277 (5.4%)N stage N035,750 (70.5%)4143 (80.6%)\<0.001 N110,084 (19.9%)709 (13.7%) N23171 (6.3%)207 (4.0%) N31700 (3.4%)86 (1.7%)Grade Well differentiated2476 (4.9%)698 (13.6%)\<0.001 Moderately differentiated8006 (15.8%)600 (11.7%) Poorly differentiated/anaplastic39,426 (77.8%)3602 (70.1%) Not recorded797 (1.6%)242 (4.7%)Chemotherapy use Yes44,365 (87.5%)4054 (78.8%)\<0.001 No6340 (12.5%)1088 (21.2%)Hormonal therapy use Yes2809 (5.5%)828 (16.1%)\<0.001 No47,896 (94.5%)4314 (83.9%)Radiation therapy Yes30,812 (60.8%)2698 (52.5%)\<0.001 No19,893 (39.2%)2444 (47.5%)Surgery Lumpectomy263,373 (52.0%)2247 (43.7%)\<0.001 Mastectomy24,332 (48.0%)2895 (56.3%)ER status Positive0 (0.0%)750 (14.6%)\<0.001 Negative50,667 (99.9%)4187 (81.4%) Not reported38 (0.1%)205 (4.0%)PR status Positive0 (0.0%)536 (10.4%)\<0.001 Negative50,669 (99.9%)4389 (85.4%) Not reported36 (0.1%)217 (4.2%)HER2 status Positive0 (0.0%)124 (2.4%)\<0.001 Negative49,541 (97.7%)2349 (45.7%) Not reported1164 (2.3%)2669 (51.9%)

[Table 2](#tbl2){ref-type="table"} shows the results of the multivariable logistic regression for characteristics associated with MBC histology. Older age, Caucasian ethnicity, higher median income, treatment at academic centers, diagnosis at earlier years, high T stage, low N stage, well-differentiated grade, mastectomy, and receipt of hormonal therapy were all factors associated with MBC histology (p \< 0.05). The 5-year overall survival for patients with MBC was 55.8%, compared to 72.0% (p \< 0.001) for those with TNBC ([Fig. 2](#fig2){ref-type="fig"}A). Due to imbalance between the groups, PSM was performed to determine OS in balanced cohorts. The groups were relatively evenly balanced in the matched cohorts ([Supplemental Tables 1 and 2](#appsec1){ref-type="sec"}). As shown in [Fig. 2](#fig2){ref-type="fig"}B, after PSM matching, patients with TNBC remained associated with a greater OS (5-year OS 65.2% vs. 60.5%, p \< 0.001). Due to differences in T and N stage, patients were compared following stratification based on stage. As shown in [Fig. 3](#fig3){ref-type="fig"}, when compared to patients with TNBC, poorer OS persisted for MBC patients based on the following subgroups: T1-T2N0 (5-year OS 63.8% vs. 79.7%, p \< 0.001), T3-T4N0 (5-year OS 33.1% vs. 62.1%, p \< 0.001), and T1-4N+ (5-year OS 42.7% vs. 56.0%, p \< 0.001). As shown in [Fig. 4](#fig4){ref-type="fig"}, ER + MBC patients who received hormonal therapy showed improved OS compared to ER + MBC patients who did not receive hormonal therapy (5-year OS 63.4% vs 49.3%, p \< 0.001). In total, 750 MBC patients had ER + status with 526 (70.1%) receiving hormonal therapy versus 224 (29.9%) who did not.Table 2Characteristics showing association with MBC using multivariate logistic regression.Table 2CharacteristicOdds Ratio95% Confidence Intervalp ValueAge ≤501 (reference) 51-641.2761.132--1.438\<0.001 ≥651.7331.479--2.030\<0.001Race White1 (reference) Black0.7590.674--0.854\<0.001 Other0.9580.787--1.1650.666Charlson Deyo Score 01 (reference) 11.0920.972--1.2270.138 ≥21.040.837--1.2920.724Insurance Status Medicaid1 (reference) Private1.2111.028--1.4260.022 Medicare1.2481.025--1.5180.318 Not Insured0.8520.621--1.1670.001 Other1.641.230--2.1860.022Median Income ≤ \$629991 (reference) ≥ \$630001.2161.112--1.330\<0.001 Not recorded1.7841.110--2.8650.017Facility Type Academic1 (reference) Nonacademic0.8790.807--0.9580.003 Not recorded0.8650.702--1.0660.173Year of Diagnosis 2004--20081 (reference) 2009--20130.2690.235--0.309\<0.001T stage T11 (reference) T22.8542.596--3.138\<0.001 T38.737.511--10.147\<0.001 T48.6036.862--10.787\<0.001N stage N01 (reference) N10.4090.363--0.462\<0.001 N20.2140.172--0.267\<0.001 N30.1700.125--0.230\<0.001Grade Well differentiated1 (reference) Moderately differentiated0.2590.218--0.308\<0.001 Poorly differentiated/anaplastic0.2950.258--0.337\<0.001 Not recorded1.0730.835--1.3780.584Chemotherapy use Yes1 (reference) No1.0690.947--1.2070.280Hormonal therapy use Yes1 (reference) No1.1720.971--1.4160.098Radiation therapy Yes1 (reference) No0.9540.859--1.0600.382Surgery Lumpectomy1 (reference) Mastectomy1.2081.082--1.350\<0.001ER status Positive1 (reference) Negative0.0000.000--0.0000.983 Not reported0.0000.000--0.0000.983PR status Positive1 (reference) Negative0.0000.000--0.0000.986 Not reported0.0000.000--0.0000.987HER2 status Positive1 (reference) Negative0.0000.000--0.0000.994 Not reported0.0000.000--0.0000.994Fig. 2Kaplan-Meier overall survival curves comparing the two cohorts in (A) all patients and (B) the propensity matched population.Fig. 2Fig. 3Kaplan-Meier overall survival curves comparing the two cohorts in (A) patients with pT1-T2N0 status, (B) and patients with pT3-T4N0 status, and (C) patients with pT1-4N + status. MBC was associated with poorer OS when compared to TNBC (p \< 0.001).Fig. 3Fig. 4Kaplan-Meier overall survival curves comparing ER + MBC patients based on receipt of hormonal therapy.Fig. 4

Results of Cox univariate and multivariate analysis to determine factors associated with overall survival are displayed in [Table 3](#tbl3){ref-type="table"}. Several factors were associated with improved overall survival on univariate analysis, including TNBC, younger age, lower nodal disease burden, Charlson Deyo score of 0, private insurance, median income ≥ \$63,000, receipt of treatment at academic centers, diagnosis from 2009 to 2013, T1 status, moderately-differentiated disease, chemotherapy use, RT use, hormonal therapy use, and treatment with lumpectomy ([Table 3](#tbl3){ref-type="table"}). On multivariable Cox regression analysis, factors associated with improved OS were TNBC disease, younger age, Charlson Deyo score 0, higher socioeconomic status, earlier year of diagnosis, earlier T and N stage of disease, chemotherapy use, hormonal therapy use, and RT use.Table 3Univariate and Multivariate Cox regression analysis of factors predictive of overall survival for all patients.Table 3CharacteristicUnivariate analysisMultivariate analysisHazard Ratio95% confidence intervalP valueHazard ratio95% confidence intervalP valueTriple-negative1 (reference)1 (reference)Metaplastic1.4751.393--1.562\<0.0011.3101.217--1.410\<0.001Age ≤50 (first)1 (reference)1 (reference) 51--640.9500.899--1.0040.0681.0460.984--1.1110.148 ≥651.7331.647--1.824\<0.0011.4271.319--1.545\<0.001Race White1 (reference)1 (reference) Black1.1201.063--1.180\<0.0011.0541.000--1.1120.052 Other0.8360.752--0.9290.0010.8820.794--0.9800.020Charlson Deyo Score 01 (reference)1 (reference) 11.4531.377--1.532\<0.0011.2421.176--1.311\<0.001 ≥22.4822.285--2.695\<0.0011.8591.709--2.021\<0.001Insurance Status Medicaid1 (reference)1 (reference) Private0.5520.515--0.592\<0.0010.7410.690--0.795\<0.001 Medicare1.1171.043--1.1970.0020.9830.900--1.0730.700 Not Insured0.9310.817--1.0600.2800.990.869--1.1270.878Other0.6670.571--0.778\<0.0010.7770.664--0.9080.001Median Income ≤ \$629991 (reference)1 (reference) ≥ \$630000.7670.732--0.802\<0.0010.9010.860--0.944\<0.001 Not recorded2.4792.009--3.059\<0.0012.3301.887--2.878\<0.001Facility Type Academic1 (reference)1 (reference) Nonacademic1.1121.066--1.161\<0.0011.0380.994--1.0840.089 Not recorded0.8970.820--0.9800.0160.9940.901--1.0970.908Year of Diagnosis 2004--20081 (reference)1 (reference) 2009--20130.8170.763--0.874\<0.0011.1041.019--1.1950.015T stage T11 (reference)1 (reference) T22.1742.074--2.278\<0.0011.7481.664--1.837\<0.001 T35.3455.015--5.696\<0.0013.2122.90--3.449\<0.001 T49.3928.664--10.181\<0.0014.2973.931--4.697\<0.001N stage N01 (reference)1 (reference) N12.0431.945--2.146\<0.0011.9001.804--2.001\<0.001 N24.2594.008--4.525\<0.0013.4733.249--3.714\<0.001 N36.8296.376--7.315\<0.0015.1424.766--5.547\<0.001Grade Well differentiated1 (reference)1 (reference) Moderately differentiated0.7280.658--0.807\<0.0010.8460.763--0.9380.002 Poorly differentiated/anaplastic0.9490.869--1.0350.2381.0310.943--1.1270.501 Not recorded0.5300.433--0.648\<0.0010.6360.519--0.779\<0.001Chemotherapy use Yes1 (reference)1 (reference) No1.3711.298--1.447\<0.0011.5271.438--1.621\<0.001Hormonal therapy use Yes1 (reference)1 (reference) No1.1271.036--1.2260.0051.1331.035--1.2400.007Radiation therapy Yes1 (reference)1 (reference) No1.4451.387--1.504\<0.0011.4751.405--1.549\<0.001Surgery Lumpectomy1 (reference)1 (reference) Mastectomy2.0741.988--2.163\<0.0011.0440.991--1.1000.106ER status Positive1 (reference)1 (reference) Negative0.8410.726--0.9760.0221.0500.872--1.2650.608 Not reported1.5181.185--1.9440.0011.1020.643--1.8880.724PR status Positive1 (reference)1 (reference) Negative0.9440.788--1.1310.5351.1910.961--1.4760.111 Not reported1.7691.357--2.305\<0.0011.4360.836--2.4650.189HER2 status Positive1 (reference) Negative0.9850.628--1.5450.946 Not reported1.3740.873--2.1620.169

4. Discussion {#sec4}
=============

The present study is the largest to date with over 5,000 MBC and 50,000 TNBC patients to compare the clinical characteristics, national practice patterns, and outcomes between patients with either TNBC or MBC. As has been demonstrated in previously published reports, MBC patients were found to have poorer OS compared to those with TNBC \[[@bib4],[@bib5],[@bib14],[@bib15]\].

Additionally, MBC patients had different clinical and pathologic characteristics than TNBC patients, including a higher proportion of patients with well differentiated disease, more advanced T stage, and less advanced or similar N stage. This is concordant with a prior retrospective study comparing patients with MBC to patients with typical invasive breast ductal carcinoma \[[@bib6]\], as well as smaller single institution studies comparing characteristics of patients with MBC to patients with TNBC \[[@bib4],[@bib5]\]. While TNBC disease was associated with improved OS when comparing all patients, due to the differences in stage as well as grade between these two patient cohorts, it was important to compare patients in more balanced groups. Worse survival with MBC persisted when comparing the propensity matched cohorts, and also after stratifying patients by stage. These results are in line with previously published reports comparing outcomes for patients with TNBC disease to those with MBC. In a retrospective study of 46 MBC and 508 TNBC patients, El Zein et al. also employed matching (40 MBC and 40 TNBC) using a variety of covariates, and found that patients with MBC had worse disease-free survival and OS compared to patients with TNBC (p \< 0.05) \[[@bib5]\]. In another study by Lee et al. comparing 67 MBC and 520 TNBC patients, the 5-year OS rate for MBC patients was 53.7% compared to 84.6% for TNBC patients and 5-year disease-free survival (DFS) was 45.6% compared to 81.6% (p \< 0.001 for all) \[[@bib15]\]. After matching and stratifying by stage, significantly worse DFS and OS were noted only for stage II MBC versus TNBC patients. However, this study did not use one-to-one matching and had a relatively small sample size compared, limiting its power to draw conclusions. Additionally, there were temporal differences observed between TNBC and MBC patients, with patients with TNBC disease being diagnosed in more recent time periods. This is likely due to the lack of complete information regarding HER2 status in earlier time periods in the NCDB.

In general, the presence of nodal involvement has been considered to be the most important prognostic factor for OS and disease-free survival (DFS) in breast cancer \[[@bib32],[@bib33]\]. Consistent with this statement, TNBC patients with nodal involvement in the present study had poorer OS compared to T3-T4N0 TNBC patients (5-year OS 56.0% vs 62.1%). However, T3-T4N0 MBC patients had poorer OS compared to MBC patients with node-positive disease (5-year OS 33.1% vs 42.7%). Likewise, El Zein et al. found that T4 MBC patients had a 40% 5- year DFS and 40% 5-year OS rate compared to a 78.9% 5-year DFS and 5-year 73.1% OS rate for patients with lower T stage disease \[[@bib4]\]. Other large retrospective reviews of patients with MBC have demonstrated that tumor size/more advanced T stage are significant variables predicting for poor OS \[[@bib34],[@bib35]\]. This suggests that unlike the majority of breast cancer cases, T stage may be a more robust prognosticator for MBC than nodal status.

The most common surgical procedure for MBC patients was mastectomy, in contrast to TNBC patients, who most frequently received surgical treatment with lumpectomy for TNBC patients. This may be due to the aggressive nature of MBC, which often presents at advanced T stages, warranting a more invasive approach \[[@bib3],[@bib4]\]. Additionally, a smaller proportion of patients with MBC patients received chemotherapy than patients with TNBC patients. Previously published reports have suggested that patients with MBC have a poor response to chemotherapy without benefits in OS, distant metastasis, or local-regional recurrence \[[@bib8]\]. MBC may also have a different molecular profile than invasive ductal carcinoma, making it less responsive to systemic therapy \[[@bib1]\]. In one single-institution retrospective study with 55 Stage I-III MBC patients, 87% of patients received adjuvant chemotherapy and over 40% experienced distant metastasis \[[@bib36]\]. Thus, the chemoresistance of MBC may contribute to the frequency of metastasis. In another single-institution retrospective study with 46 MBC patients, Chen et al. found a lack of response in those receiving anthracycline, vinorelbine, or cyclophosphamide-based chemotherapy and 90% of patients receiving neoadjuvant therapy had disease progression \[[@bib37]\]. Others have found a complete response rate of only 10--17% following neoadjuvant chemotherapy in MBC patients \[[@bib38],[@bib39]\].

In general, hormonal therapy is recommended for ER+ and/or progesterone-receptor positive (PR+) breast cancer patients due to its efficacy \[[@bib40]\]. However, hormonal therapy is usually ineffective for MBC patients because the majority of the patients have triple-negative status \[[@bib41],[@bib42]\]. Furthermore, a retrospective study by Paul Wright et al. utilizing the Surveillance, Epidemiology, and End Results Database did not find a survival benefit even in patients with positive hormone-receptor MBC tumors, although this study is limited due to a lack of information on receipt of hormonal-therapy \[[@bib43]\]. In contrast, our study demonstrated that ER + MBC patients receiving hormonal therapy demonstrated improved OS compared to those who did not. This suggests that there may be subsets of MBC patients, in particular ER + patients, who may benefit from the use of hormonal therapy.

MBC tissue samples have been shown to express low levels of genes associated with cell-cell adhesion (claudin-low), but high levels of EMT and stem-cell like markers, such as elevated CD29/CD24 ratios \[[@bib44]\]. CD24 expression has also been described as a prognostic feature in various malignancies, including sarcomas \[[@bib45]\]. These distinct factors, in addition to mutations activating the phosphatidylinositol 3-kinase (PI3K/AKT) pathway may contribute to the chemoresistant profile of MBCs compared to TNBC \[[@bib46],[@bib47]\]. Our group has previously demonstrated that a smaller percentage of patients with MBC received RT than patients with TNBC disease, despite use of RT having an association with improved OS \[[@bib3]\]. Prior studies have also shown that RT may result in improved OS, local-regional recurrence rates, and disease-specific survival for MBC patients \[[@bib7]\]. These studies suggest postoperative RT should be administered in patients with MBC following lumpectomy and following mastectomy in the setting of locally advanced or node positive disease.

There are several limitations to this study. As a retrospective study, there is potential for selection bias and imbalance between the cohorts. While PSM was conducted to minimize imbalance between the arms, there may be unmeasured cofounding covariates. Second, the NCDB does not keep track of certain information such as the reason why a patient received a particular treatment or exact agents used for treatment. It also does not provide information about important high-risk features, such as lymphovascular invasion or Ki-67 proliferative index. Third, there are epithelial and mixed types of MBC, each with different subtypes. The NCDB did not provide data regarding the various subtypes and there is a lack of a central pathologic review of the diagnoses, which may influence the conclusions herein \[[@bib1],[@bib48]\]. While some did not find a significant difference in outcomes among these subtypes \[[@bib4],[@bib8]\], other studies suggest the subtypes of MBC may have different prognoses and have different rates of achieving complete pathologic response following chemotherapy \[[@bib39],[@bib49]\]. The presence of more than one metaplastic components may also be associated with poorer outcomes \[[@bib39]\]. Finally, the NCDB also does not provide information on disease-free survival, disease-specific survival, or local recurrence rates of cancer. Despite these limitations, further prospective studies are needed to corroborate the findings highlighted in this study.

5. Conclusions {#sec5}
==============

This is the largest study to date comparing clinical characteristics and outcomes of patients with MBC to patients with TNBC. MBC patients present more often with well differentiated disease, more advanced T stage, and less advanced or similar N stage than TNBC patients. A smaller percentage of MBC versus TNBC patients received RT, chemotherapy, and lumpectomy for treatments. While there may be a subset of ER + MBC patients who may respond to hormonal therapy, MBC patients, in general, have worse OS compared with TNBC patients. Further prospective studies are needed to corroborate our conclusions.
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